Search Results
Active Filters
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
Jun 02, 2026, 09:02 ET A Third Cancer Drug Just Entered the Clinic at an Under-$20-Million Company
differently the market values programs at various stages — and how much capital is chasing the same fundamental idea.Innate Pharma S.A. (NASDAQ: IPHA) is the closest mechanistic comparison. Its proprietary ANKET® platform builds multi-specific NK cell engagers — the same broad class of molecule as
More news about: USA News Group
May 18, 2026, 14:22 ET B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic
the antigen that supports the broader investment thesis around B7-H3-targeted programs at every scale.Innate Pharma S.A. (NASDAQ: IPHA) has long been one of the more prominent publicly listed pure-play NK cell engager companies, with multispecific approaches that hit triggering receptors
More news about: USA News Group